Concepedia

Collin Crowley

CC

Statistics

Publications

7

Citations

605

H-Index

7

Active since

1997

Affiliations

Pfizer (United States)(Current)

Collin Crowley is an author at Pfizer (United States) specializing in pharmacology, metabolic liver disease, and liver disease.

Publications per year

1997–2022

7

Publications

7

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez et al. · Nature Medicine · 2021 · 219 citations

, , +9

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

Trenton T. Ross, Collin Crowley, Kenneth L. Kelly et al. · Cellular and Molecular Gastroenterology and Hepatology · 2020 · 92 citations · Full text

, , +17

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

Jemy A. Gutierrez, Wei Liu, Sylvie Perez et al. · Molecular Metabolism · 2021 · 84 citations · Full text

, , +16

The Acute Effects of Exercise on Bone Turnover

L. Welsh, O. M. Rutherford, Ian James et al. · International Journal of Sports Medicine · 1997 · 80 citations

, , +15

Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

Neeta B. Amin, Santos Carvajal‐Gonzalez, Julie J. Purkal et al. · Science Translational Medicine · 2019 · 73 citations · Full text

, , +17

1–5 of 7